Visually Guided TAP Block in Laparoscopic TAPP Hernia Repair (VIS-TAP-TAPP)

November 14, 2026 updated by: Łukasz Dyśko, University of Warmia and Mazury in Olsztyn

Efficacy of Visually Guided Transversus Abdominis Plane (TAP) Block in Recovery After Laparoscopic Inguinal Hernia Repair (TAPP - Transabdominal Preperitoneal)

This prospective, randomized, placebo-controlled clinical study evaluates the effectiveness of a bilateral transversus abdominis plane (TAP) block performed under direct laparoscopic guidance in reducing postoperative pain and improving recovery after laparoscopic inguinal hernia repair using the transabdominal preperitoneal (TAPP) technique.

Adult patients undergoing elective laparoscopic TAPP hernia repair at the University Clinical Hospital in Olsztyn, Poland, are randomly assigned to two groups. In the experimental group, a bilateral TAP block is performed after establishing pneumoperitoneum, using 20 mL of 0.25% bupivacaine on each side (40 mL total; 100 mg total). In the control group, 20 mL of 0.9% sodium chloride is injected on each side (40 mL total) as a placebo, using the same technique and anatomical sites.

Participants, the operating surgeon, and the postoperative outcome assessor are blinded to treatment allocation. An unblinded investigator performs randomization and informs the operating room nurse which solution to prepare. The nurse provides the surgeon with an unlabeled, visually identical syringe without disclosing its contents. The unblinded investigator does not assess postoperative outcomes or collect postoperative data. The outcome assessor is not present during randomization or injection and remains unaware of allocation during postoperative assessments.

Both groups receive the same standardized general anesthesia protocol and postoperative analgesic regimen. Postoperative assessments include pain intensity measured using the Visual Analogue Scale (VAS), analgesic consumption, the need for rescue opioid analgesia, time to first analgesic request, time to mobilization, readiness for discharge assessed using the Post-Anesthetic Discharge Scoring System (PADSS), and adverse events.

The study compares postoperative pain and recovery outcomes between patients receiving laparoscopically guided TAP block with bupivacaine and those receiving placebo saline injections.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Postoperative pain remains an important factor limiting early mobilization and recovery after laparoscopic inguinal hernia repair using the transabdominal preperitoneal (TAPP) technique. Multimodal analgesia combines systemic analgesics with additional approaches, including regional anesthesia. A transversus abdominis plane (TAP) block targets nerves supplying the abdominal wall and can be performed under direct laparoscopic guidance during surgery.

This single-center, prospective, randomized, placebo-controlled study evaluates the effect of a laparoscopically guided bilateral TAP block on postoperative pain and recovery after elective TAPP inguinal hernia repair at the University Clinical Hospital in Olsztyn, Poland.

The planned sample size is 116 adult participants, allocated in a 1:1 ratio to two groups of 58 participants each:

Experimental group: After pneumoperitoneum is established and the laparoscope is introduced, a bilateral TAP block is performed under direct laparoscopic guidance before mesh placement. Bupivacaine 0.25% is injected at a volume of 20 mL per side, corresponding to 50 mg per side and 100 mg in total. The injection site is approximately 2 cm below the costal margin in the anterior axillary line. Correct needle placement is confirmed visually by the characteristic elevation of the transversus abdominis muscle layer, known as the "Doyle's bulge sign."

Placebo control group: Participants undergo the same TAPP repair and receive bilateral injections of 0.9% sodium chloride, 20 mL per side (40 mL total), using the same injection technique and anatomical sites as in the experimental group.

Participants, the operating surgeon, and the postoperative outcome assessor are blinded to treatment allocation. An unblinded investigator performs randomization and informs the operating room nurse which solution to prepare. The nurse provides the surgeon with an unlabeled, visually identical syringe without disclosing its contents. The unblinded investigator does not assess postoperative outcomes or collect postoperative data. The outcome assessor is not present during randomization or injection and remains unaware of allocation during postoperative assessments.

Both groups receive the same standardized general anesthesia protocol and postoperative analgesic regimen. Analgesic administration and the timing of rescue medication are recorded.

Postoperative pain intensity is assessed using the Visual Analogue Scale (VAS; 0-10) at 0, 2, and 6 hours after the end of surgery. Site-specific assessments include the umbilical port site, the working trocar site on the operated side, the working trocar site on the opposite side, the operated groin, and the ipsilateral testicle, where applicable. Additional assessments include time to first mobilization, analgesic consumption, rescue analgesic use, and readiness for discharge using the Post-Anesthetic Discharge Scoring System (PADSS) at 6 hours. Adverse events, including hematoma, swelling, subcutaneous emphysema, and transient lower limb weakness, are recorded during the 6-hour postoperative observation period.

Exclusion criteria include chronic analgesic use, chronic pain syndromes, psychiatric disorders, alcohol or opioid dependence, recurrent hernias, and emergency surgery. All participants provide written informed consent before enrollment.

The primary outcome is postoperative pain intensity at rest measured using the VAS at 2 hours after the end of surgery. Secondary outcomes include pain intensity at 0 and 6 hours, site-specific pain intensity, analgesic consumption during the first 6 hours, the proportion of participants requiring rescue opioid analgesia, time to first analgesic request, time to mobilization, readiness for discharge assessed using PADSS at 6 hours, and adverse events.

Statistical analyses compare postoperative pain, analgesic requirements, and recovery outcomes between the bupivacaine and placebo groups. The study hypothesis is that a laparoscopically guided bilateral TAP block with bupivacaine reduces postoperative pain and improves early recovery compared with placebo saline injections.

Study Type

Interventional

Enrollment (Actual)

116

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Warmisko-mazurskie
      • Olsztyn, Warmisko-mazurskie, Poland, 10-041
        • University Clinical Hospital in Olsztyn, Department of General and Oncological Surgery

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age 18-80 years
  • Elective laparoscopic inguinal hernia repair using the TAPP (Transabdominal Preperitoneal) technique
  • ASA physical status I-III
  • Ability to provide written informed consent
  • No contraindications to regional anesthesia or local anesthetic administration

Exclusion Criteria:

  • Recurrent or strangulated inguinal hernia
  • Emergency surgery
  • Chronic pain syndromes or preoperative opioid use
  • Known allergy or hypersensitivity to local anesthetics (bupivacaine or similar)
  • Severe hepatic or renal impairment
  • Psychiatric disorders or inability to provide informed consent
  • Conversion to open surgery during the procedure
  • Technical difficulties preventing TAP block administration

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: TAP Block Group (Laparoscopic TAP Block with Bupivacaine)

After pneumoperitoneum is established and the laparoscope is introduced, a bilateral Transversus Abdominis Plane (TAP) block is performed under direct laparoscopic vision. Using a needle and syringe, 20 ml of 0.25% bupivacaine is injected on each side, approximately 2 cm below the costal margin in the anterior axillary line. The correct placement of the local anesthetic is confirmed by the visible "Doyle's bulge sign." Patients receive standard general anesthesia and postoperative pain management identical to the control group.

A bilateral transversus abdominis plane (TAP) block is performed under direct laparoscopic guidance after pneumoperitoneum is established and before mesh placement during TAPP inguinal hernia repair. Using a needle and syringe, 20 mL of 0.25% bupivacaine is injected on each side (40 mL total; 100 mg total), approximately 2 cm below the costal margin in the anterior axillary line. Correct needle placement is confirmed visually by the characteristic "Doyle's bulge sign." This technique allows direct laparoscopic visualization of the injection site.

Other Names:
  • TAPP with TAP Block
Placebo Comparator: Control Group (Placebo Saline Injection)

Participants undergo standard laparoscopic inguinal hernia repair using the transabdominal preperitoneal (TAPP) technique. Instead of bupivacaine, 20 mL of 0.9% sodium chloride is injected on each side (40 mL total) as a placebo, using the same visually guided injection technique and anatomical sites as in the experimental group. All patients receive the same standardized general anesthesia protocol and postoperative analgesic regimen as those in the experimental group.

Bilateral injection of 0.9% sodium chloride, 20 mL per side (40 mL total), into the transversus abdominis plane under laparoscopic visual guidance. The placebo is administered at the same anatomical sites and using the same technique as bupivacaine in the experimental group. An operating room nurse prepares a visually identical syringe without disclosing its contents to the operating surgeon.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postoperative pain intensity at rest (VAS score) at 2 hours after TAPP hernia repair
Time Frame: 2 hours after the end of surgery

Postoperative pain intensity at rest is assessed using the Visual Analogue Scale (VAS), ranging from 0 (no pain) to 10 (worst pain imaginable), at 2 hours after the end of surgery. Assessment is performed by an outcome assessor blinded to treatment allocation. Scores are compared between the bupivacaine TAP block group and the placebo saline injection group.

2 hours after the end of surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postoperative pain intensity at rest (VAS score) at 0 and 6 hours after surgery
Time Frame: 0 and 6 hours after the end of surgery

Postoperative pain intensity at rest is assessed using the Visual Analogue Scale (VAS), ranging from 0 (no pain) to 10 (worst pain imaginable), immediately after surgery (0 hours) and at 6 hours after the end of surgery. Assessment is performed by an outcome assessor blinded to treatment allocation.

0 and 6 hours after the end of surgery
Time to first mobilization
Time Frame: Within 6 hours after the end of surgery

The time (in hours) from the end of surgery to the patient's first ambulation will be recorded.

Within 6 hours after the end of surgery
Postoperative recovery score (PADSS)
Time Frame: 6 hours after surgery

Recovery will be assessed using the Post Anesthesia Discharge Scoring System (PADSS), 0-10; higher scores indicate greater readiness for discharge. A score ≥9 will indicate readiness for discharge.

6 hours after surgery
Incidence of postoperative complications
Time Frame: Within 6 hours after the end of surgery

Early postoperative complications such as hematoma, swelling, subcutaneous emphysema, or transient lower limb weakness will be recorded.

Within 6 hours after the end of surgery
Participants requiring rescue opioid analgesia
Time Frame: First 6 hours after the end of surgery

Proportion of participants receiving rescue oxycodone during the first 6 postoperative hours.

First 6 hours after the end of surgery
Total oxycodone consumption
Time Frame: First 6 hours after the end of surgery

Total dose of oxycodone administered to each participant, expressed in milligrams.

First 6 hours after the end of surgery
Total metamizole consumption
Time Frame: First 6 hours after the end of surgery

Total dose of metamizole administered to each participant, expressed in grams.

First 6 hours after the end of surgery
Total paracetamol consumption
Time Frame: First 6 hours after the end of surgery

Total dose of paracetamol administered to each participant, expressed in grams.

First 6 hours after the end of surgery
Time to first analgesic request
Time Frame: First 6 hours after the end of surgery

Time in hours from the end of surgery to the participant's first request for analgesic medication.

First 6 hours after the end of surgery
Site-specific postoperative pain intensity
Time Frame: 0, 2, and 6 hours after the end of surgery

Pain intensity is assessed using the VAS (0-10; higher scores indicate worse pain) separately at the umbilical port site, ipsilateral and contralateral working trocar sites, operated groin, and ipsilateral testicle, where applicable.

0, 2, and 6 hours after the end of surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Marek Kowalczyk, PhD, MD, Clinic of Oncological and General Surgery, University Clinical Hospital in Olsztyn, Olsztyn, Poland

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 4, 2025

Primary Completion (Actual)

October 31, 2026

Study Completion (Actual)

October 31, 2026

Study Registration Dates

First Submitted

November 23, 2025

First Submitted That Met QC Criteria

November 23, 2025

First Posted (Actual)

December 4, 2025

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 14, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • UWM-TAP-TAPP-2025
  • 19/2025/IX (Other Identifier: Ethics Committee Approval Number - Warmian-Masurian Chamber of Physicians in Olsztyn)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data (IPD) will not be shared because this is a single-center, investigator-initiated academic study involving a limited number of participants. The collected data include sensitive personal and clinical information that cannot be fully anonymized without compromising data integrity. Only aggregated, de-identified results will be published in peer-reviewed journals and conference presentations.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.